Karyopharm Therapeutics Inc.
KPTI
$1.61
-$0.09-5.03%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -224.74M | -194.97M | -196.04M | -124.62M | -123.57M |
| Total Depreciation and Amortization | 149.00K | 230.00K | 296.00K | 358.00K | 320.00K |
| Total Amortization of Deferred Charges | 10.17M | 10.34M | 10.55M | 10.46M | 10.06M |
| Total Other Non-Cash Items | 124.20M | 91.64M | 81.56M | -7.73M | -18.17M |
| Change in Net Operating Assets | 24.87M | 33.65M | 28.27M | 32.18M | 28.41M |
| Cash from Operations | -65.35M | -59.11M | -75.37M | -89.35M | -102.94M |
| Capital Expenditure | -- | -- | -- | 53.00K | 53.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.97M | 31.29M | 43.38M | 53.12M | 55.79M |
| Cash from Investing | 2.97M | 31.29M | 43.38M | 53.18M | 55.84M |
| Total Debt Issued | 27.25M | 27.25M | 27.25M | 0.00 | 83.30M |
| Total Debt Repaid | -250.00K | -250.00K | -250.00K | -- | -- |
| Issuance of Common Stock | 59.96M | 59.74M | 9.51M | 1.04M | 1.04M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8.37M | -6.89M | -6.46M | 0.00 | -83.30M |
| Cash from Financing | 78.60M | 79.85M | 30.05M | 1.04M | 1.04M |
| Foreign Exchange rate Adjustments | 5.00K | 17.00K | 20.00K | -5.00K | 29.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16.22M | 52.04M | -1.92M | -35.15M | -46.04M |